RSS-Feed abonnieren
DOI: 10.1055/s-0042-104594
Systemtherapie des metastasierten Nierenzellkarzinoms
Systemic therapy of metastatic renal cell carcinomaPublikationsverlauf
Publikationsdatum:
31. März 2016 (online)
![](https://www.thieme-connect.de/media/dmw/201607/lookinside/thumbnails/0466_10-1055-s-0042-104594-1.jpg)
Zusammenfassung
In der Erstlinientherapie des metastasierten Nierenzellkarzinoms stehen weiterhin die Tyrosinkinasehemmer (TKI) Pazopanib und Sunitinib sowie für Patienten mit günstigem oder intermediärem Risikoprofil auch IFNα/Bevacizumab sowie für Hochrisikopatienten der mTOR Inhibitor Temsirolimus zur Verfügung. In der Zweitlinientherapie nach Zytokintherapie können Axitinib oder Pazopanib und nach Vortherapie mit einer TKI/VEGF gerichteten Therapie Axitinib oder Everolimus eingesetzt werden. Neue Substanzen wie der PD1 Antikörper Nivolumab und der Multikinasehemmer Cabozantinib haben in der Zweitlinie einen Überlebensvorteil gegenüber Everolimus gezeigt und sollten daher nach Zulassung in der Zweit- und Drittlinie aufgrund des Vorteils beim Gesamtüberleben eingesetzt werden.
Abstract
In metastatic ccRCC , the treatment options in 1st line treatment are still the tyrosinkinase inhibitors (TKI) pazopanib and sunitinib, for patients with low or intermediate risk additionally IFNα/bevacizumab and for high risk patients the mTOR inhibitor temsirolimus. In 2nd line following cytokine therapy, axitinib or pazopanib and following TKI /VEGF directed therapy axitinib or everolimus may be administered. New upcoming agents in RCC are the PD1 antibody nivolumab and the multikinase inhibitor Cabozantinib, which both showed an OS advantage compared to everolimus. After marketing authorization in Europe, these agents should therefore be preferred in 2nd and 3rd line therapy. Further agents are under investigation.
-
Literatur
- 1 Kaatsch P, Spix C, Katalinic A et al. Krebs in Deutschland 2009/2010. In Berlin: Robert Koch-Institut; Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. 2013
- 2 Corgna E, Betti M, Gatta G et al. Renal cancer. Crit Rev Oncol Hematol 2007; 64: 247-262
- 3 Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Fourth edition. IARC; Lyon: 2016
- 4 Miller K, Bergmann L, Gschwend J et al. Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms. Aktuelle Urol 2015; 46: 151-157
- 5 S3 Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. 2015 www.awmf.org/uploads/tx_szleitlinien/043-017Ol-l_S3_Nierenzellkarzinom_2015-09.pdf (Letzter Zugriff 9.3.2016)
- 6 Fisher RI, Rosenberg SA, Fyfe G. Longterm survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1) S55-S57
- 7 Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer 2009; 115: 2321-2326
- 8 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111
- 9 Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590
- 10 Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068
- 11 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
- 12 Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-731
- 13 Gore ME, Szczylik C, Porta C et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015; 113: 12-19
- 14 Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939
- 15 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265
- 16 Motzer RJ, Barrios CH, Kim TM et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32: 2765-2772
- 17 Eichelberg C, Vervenne WL, De Santis M et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol 2015; 68: 837-847
- 18 Motzer RJ, Hutson TE, Glen H et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16: 1473-1482
- 19 Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1814-1823
- 20 Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813
- 21 Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420
- 22 Powles T, Staehler M, Ljungberg B et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 2016; 69: 4-6
- 23 Vera-Badillo FE, Templeton AJ, Duran I et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 2015; 67: 740-749
- 24 Armstrong AJ, Halabi S, Eisen T et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 2016; epub ahead of print
- 25 Tannir NM, Jonasch E, Albiges L et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2015; DOI: 10.1016/j.eururo.2015.10.049.
- 26 Bergmann L, Grünwald V, Maute L et al. A Prospective Randomized Phase-II Trial with Temsirolimus vs. Sunitinib in non-clear Renal Cell Carcinoma (C-II-006). ECCO 2015; #2617
- 27 Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454-463
- 28 Ko JJ, Xie W, Kroeger N et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015; 16: 293-300